Brokers Issue Forecasts for ABOS FY2026 Earnings

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Acumen Pharmaceuticals in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will earn ($1.21) per share for the year. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share.

A number of other equities analysts have also commented on ABOS. UBS Group cut their price target on shares of Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, March 28th. HC Wainwright cut their target price on Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating on the stock in a report on Friday, March 28th.

Acumen Pharmaceuticals Stock Performance

Shares of NASDAQ:ABOS opened at $1.17 on Wednesday. Acumen Pharmaceuticals has a 1 year low of $0.86 and a 1 year high of $3.60. The company’s 50 day simple moving average is $1.04 and its 200 day simple moving average is $1.41. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.43 and a quick ratio of 10.43. The stock has a market capitalization of $70.87 million, a price-to-earnings ratio of -0.86 and a beta of 0.05.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.08. During the same quarter last year, the company earned ($0.25) earnings per share.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC boosted its position in shares of Acumen Pharmaceuticals by 44.2% during the 4th quarter. SG Americas Securities LLC now owns 25,631 shares of the company’s stock worth $44,000 after purchasing an additional 7,859 shares in the last quarter. Deutsche Bank AG increased its stake in Acumen Pharmaceuticals by 468.7% during the 4th quarter. Deutsche Bank AG now owns 96,995 shares of the company’s stock valued at $167,000 after purchasing an additional 79,940 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Acumen Pharmaceuticals by 1,387.2% during the fourth quarter. JPMorgan Chase & Co. now owns 937,908 shares of the company’s stock worth $1,613,000 after buying an additional 874,842 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Acumen Pharmaceuticals by 427.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 20,624 shares of the company’s stock valued at $35,000 after buying an additional 16,714 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Acumen Pharmaceuticals by 73.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 98,016 shares of the company’s stock valued at $169,000 after buying an additional 41,460 shares during the last quarter. 71.01% of the stock is owned by institutional investors.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.